Clinical and Experimental Nephrology

, Volume 22, Issue 3, pp 597–602 | Cite as

Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus

  • Yoko Wada
  • Hisashi Hasegawa
  • Takako Saeki
  • Satoshi Ito
  • Takeshi Kuroda
  • Masaaki Nakano
  • Ichiei Narita
Original Article

Abstract

Objective

Using a single-center cohort of Japanese patients with SLE, we attempted to clarify the long-term outcome and factors associated with damage accrual using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).

Methods

We examined a cohort of 557 patients who had been referred to Niigata University Hospital and diagnosed as having SLE between 1961 and 2013. The patients’ data at the latest visit were collected from their clinical records, and causes of death were defined on the basis of those data. Survival from the time of diagnosis was calculated by the Kaplan–Meier method. The SDI was calculated and analyzed using Spearman’s correlation coefficient and stepwise multiple regression analysis to reveal the factors associated with any organ damage.

Results

Data from 458 of the patients were successfully obtained. The overall 5-year survival rate was 92.2%, and patients diagnosed after 2000 had a significantly high 5-year survival rate of 96.4%. Stepwise multiple regression analysis selected serum creatinine levels (B = 0.6051, p < 0.0001), age (standardized beta = 0.2762, p < 0.001), hypertension (standardized beta = 0.2267, p < 0.001), and antiphospholipid antibody syndrome (standardized beta = 0.1533, p = 0.005) as positive independent variables, whereas administration of bisphosphonate (standardized beta = − 0.1295, p = 0.016) was selected as a negative independent variable.

Conclusion

These results suggest that Japanese patients with SLE have a favorable long-term prognosis, and also indicate that disease control as well as management of chronic complications such as hypertension and osteoporosis has possible effects for prevention of organ damage.

Keywords

Systemic lupus erythematosus SLICC/ACR Damage Index (SDI) Hypertension Bisphosphonate 

Notes

Acknowledgements

We are grateful to Professor Naohito Tanabe, University of Niigata Prefecture, for his kind advice regarding statistical analyses in this study.

Compliance with ethical standards

Conflict of interest

All authors do not have any conflict of interest regarding to the study.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 1754) and with the Declaration of Helsinki and the ethical guidelines for epidemiological studies issued by the Ministry of Health, Labour and Welfare of Japan.

Informed consent

Because data were retrospectively obtained from medical records, informed consent was not obtained in accordance with the above ethical guidelines.

References

  1. 1.
    Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Med (Baltim). 2006;85:147–56.CrossRefGoogle Scholar
  2. 2.
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Sutton EJ, Davidson JE, Bruce IN. The Systemic Lupus International Collaborating Clinics (SLICC) Damage Index: a systematic literature review. Semin Arthritis Rheum. 2013;43:352–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus. The Hopkins Lupus Cohort. Arthritis Rheum. 2012;64:4021–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bruce IN, O’Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Linics (SLICC) inception cohort. Ann Rheum Dis. 2015;74:1706–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology. 2015;54:836–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006;33:1570–7.PubMedGoogle Scholar
  9. 9.
    Stoll T, SutcliffeN Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus- a 5-yr prospective study. Rheumatology. 2004;43:1039–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Sato H, Miida T, Wada Y, et al. Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta. 2007;385:35–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex, and disease duration in systemic lupus erythematosus. Rheumatol (Oxf). 2003;42:276–9.CrossRefGoogle Scholar
  12. 12.
    Chaiamnuay S, Bertoli AM, Roseman JM, McGwin G, Apte M, Duran S, et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINALV). Ann Rheum Dis. 2007;66:618–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56:2092–4.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cooper GS, Parks CG, Treadwell EL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the Southeastern United States. Lupus. 2002;11:161–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039–46.CrossRefPubMedGoogle Scholar
  16. 16.
    Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMedGoogle Scholar
  18. 18.
    Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.CrossRefPubMedGoogle Scholar
  20. 20.
    Ugarte-Gil MF, Pons-Estel GJ, Molineros J, Wojdyla D, McGwin G, Nath SK, et al. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheumatology. 2016;55:436–40.PubMedGoogle Scholar
  21. 21.
    Gomez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcon GS, Costenbader KH. Racial/ethnic variation in all-cause mortality among United States Medicaid recipients with systemic lupus erythematosus. a Hispanic and Asian paradox. Arthritis Rheum. 2015;67:752–60.CrossRefGoogle Scholar
  22. 22.
    Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32:337–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Themaer M, Hernan MA, Zhang Y, Cotter D, Petri M. Relationship between prednisolone, Lupus activity and permanent organ damage. J Rheumatol. 2009;36:560–4.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2017

Authors and Affiliations

  • Yoko Wada
    • 1
  • Hisashi Hasegawa
    • 2
  • Takako Saeki
    • 3
  • Satoshi Ito
    • 4
  • Takeshi Kuroda
    • 5
  • Masaaki Nakano
    • 6
  • Ichiei Narita
    • 1
  1. 1.Division of Clinical Nephrology and Rheumatology, Kidney Research CenterNiigata University Graduate School of Medical and Dental SciencesNiigataJapan
  2. 2.Division of Clinical Nephrology and RheumatologyNiigata City General HospitalNiigataJapan
  3. 3.Division of Clinical Nephrology and RheumatologyNagaoka Red Cross HospitalNagaokaJapan
  4. 4.Division of RheumatologyNiigata Prefectural Rheumatic CenterShibataJapan
  5. 5.Health Administration OfficeNiigata UniversityNiigataJapan
  6. 6.School of Health Sciences, Faculty of MedicineNiigata UniversityNiigataJapan

Personalised recommendations